The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.

Publikation

The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.

Wissenschaftlicher Artikel/Review - 15.04.2007

Horger Marius, Kanz Lothar, Denecke Barbara, Vonthein Reinhard, Pereira Philippe, Claussen Claus Detlef, Driessen Christoph

Zitation

Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen C, Driessen C. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007; 109:1617-26.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Cancer 2007; 109

Veröffentlichungsdatum

15.04.2007

ISSN (Druck)

0008-543X

Seiten

1617-26

Kurzbeschreibung/Zielsetzung

The objectives of this study were to assess the status and clinical course of patients with multiple myeloma based on the direct visualization of changes in medullary, extramedullary, and focal osteolytic myeloma involvement by using whole-body, low-dose, multidetector computed tomography (WBLD-MDCT) and to compare those results with an assessment based on conventional hematologic parameters.